NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
NCCN Guidelines® recommend sevabertinib (HYRNUO®) as a 1L treatment option (NCCN Category 2A) for HER2-mutated NSCLC, and as a preferred 2L+ treatment option for certain patients who have received prior systemic therapy.3
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
ACCESS AND FINANCIAL SUPPORT IS AVAILABLE
Explore financial assistance information, patient support resources, and downloadable tools to help navigate patient access.
See financial assistance options Explore resourcesBayer financial support
$0 co-pay program
Educational resources for you and your patients
ABBREVIATIONS
1L=first line; BICR=blinded independent central review; CI=confidence interval; CR=complete response; DoR=duration of response; FDA=Food and Drug Administration; NE=not estimable; ORR=objective response rate; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; TKI=tyrosine kinase inhibitor.
REFERENCES
- HYRNUO (sevabertinib). Prescribing Information. 2026.
- ClinicalTrials.gov. NCT05099172. Accessed May 21, 2026. https://clinicaltrials.gov/study/NCT05099172
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V9.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed October 12, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org.